Predictors in routine practice of 6-min walking distance and oxygen desaturation in patients with COPD: impact of comorbidities

This article was published in the following Dove Press journal:
International Journal of Chronic Obstructive Pulmonary Disease

Thierry Perez,¹ Gaëtan Deslée,²
Pierre Régis Burgel,³
Denis Caillaud,⁴
Olivier Le Rouzic,¹
Maeva Zysman,⁵
Roger Escamilla,⁶ Gilles Jebrak,⁷
Pascal Chanez,⁸ Isabelle Court-
Fortune,⁹ Graziella Brinchault-
Rabin,¹⁰ Pascale Nesme-
Meyer,¹¹ Jean-
Louis Paillasseur,¹²
Nicolas Roche³

On behalf of the Initiatives
BPCO Scientific Committee

¹CHU Lille, Department of Respiratory Diseases, F-59000 Lille and Univ. Lille, Center for Infection and Immunity of Lille, INSERM U1019 - CNRS UMR 8204, F-59000, Lille, France; ²Department of Respiratory Diseases, Maison Blanche Hospital, CHU de Reims, INSERM UMRS 1250, Reims, France; ³Respiratory and Intensive Care Medicine Department, Cochin Hospital, AP-HP and Paris Descartes University (EA 2511), Sorbonne Paris Cité, Paris, France; ⁴Department of Respiratory Diseases, Gabriel Montpied Hospital, CHU de Clermont Ferrand, Clermont Ferrand, France; ⁵Department of Respiratory Diseases, CHU Nancy, Nancy, France; ⁶Department of Respiratory Diseases, CHU Toulouse, Toulouse, France; ⁷Department of Respiratory Diseases, Hôpital Bichat, APHP, Paris, France; ⁸Department of Respiratory Diseases, AP-HM, Université de Méditerranée, Inserm U 1077, Marseille, France; ⁹Department of Respiratory Diseases, CHU Saint Etienne, Saint Etienne, France; ¹⁰Department of Respiratory Diseases, Pontchaillou Hospital, CHU Rennes, Rennes, France; ¹¹Department of Respiratory Diseases, La Croix Rousse Hospital, Lyon, France; ¹²EFFI-STAT, Paris, France

Correspondence: Thierry Perez
Hôpital Calmette, CHRU de Lille, Bd J
Leclercq, Lille cedex 59037, France
Tel +33 32 044 5619
Email thierry.perez@chru-lille.fr

Background: The 6-min walk test (6MWT) allows exercise tolerance to be assessed, and it has a significant prognostic value in COPD. The goal of this study was to analyse the determinants (obtained in routine practice) of a low 6-min walking distance (6MWD) and exercise-induced desaturation (EID) in COPD, including comorbidities.

Methods: Patients were recruited from the real-life French COPD cohort “Initiatives BPCO”. A low 6MWD was defined as <350 m. EID was defined by a minimum pulse oxygen saturation (SpO₂)<90% and delta SpO₂≥4% from baseline. Multivariate logistic regression analyses assessed the influence on 6MWD and EID of age, sex, obesity (body mass index, BMI >30 kg/m²), low BMI (BMI <18.5 kg/m²), modified Medical Research Council (mMRC) dyspnea scale, FEV₁% pred, FVC % pred, hyperinflation and comorbidities including cardiovascular diseases.

Results: Among 440 patients with available 6MWT data, a 6MWD <350 m was found in 146 patients (33%), which was positively associated in multivariate analyses with age and mMRC and negatively with resting SpO₂ and FVC % pred (rescaled r²=0.34), whereas no comorbidity was associated with a low 6MWD. EID was found in 155 patients (35%). This was positively associated with hypertension and negatively with age, obesity, FEV₁% pred and resting SpO₂ (rescaled r²=0.37).

Conclusion: 6MWD and EID exhibit different determinants in COPD with a minor impact of comorbidities limited to hypertension in EID and to obesity, which was unexpectedly associated with less EID. Other variables including age, routine resting lung function and SpO₂ were weakly associated with 6MWD and EID. Altogether, these results suggest that 6MWT performance remains difficult to predict with routine clinical/functional parameters.

Keywords: 6-min walk test, distance, COPD, obesity, comorbidities, severity

Background

COPD is worldwide a leading cause of mortality and morbidity^{1,2} associated with progressive airflow limitation. Until recently, COPD severity was mainly defined by the level of post-bronchodilator FEV₁.³ Dyspnea and exercise limitation are the predominant consequences of COPD in stable condition and appear now as major indexes of disease severity and prominent targets of treatment. The 6-min walk test (6MWT) is a widely used field test to assess exercise performance with an abundant literature supporting its clinical relevance.^{4,5} The distance walked at the end of the test (6MWD) is the primary outcome and a strong prognostic factor in COPD, either as a single parameter or as part of a multidimensional index.⁶⁻⁸ Several studies suggested the

350 m value as a relevant prognostic cutoff.^{6,9–11} The multi-dimensional BODE index (BMI, obstruction, dyspnea and exercise) also integrates an upper cutoff of 350 m for 6MWD,⁷ and a low baseline value of 6MWD is highly predictive of a worsening in BODE score at 2 to 3 years.¹²

Exercise-induced desaturation (EID) is common in COPD and routinely assessed during the 6MWT. Various definitions have been used to characterize significant EID. The most common definition is a pulse oxygen saturation (SpO₂) drop >4% from baseline and/or a lowest SpO₂<90% during the 6MWT.^{9,13} The predicting factors of EID in COPD are poorly known with conflicting results from different studies, usually demonstrating resting SpO₂ and PaO₂ as significant predictors.^{9,14–16} The negative prognostic value of EID during the 6MWT is confirmed by several studies.^{8,13,17}

Comorbidities are frequent in COPD, with a significant impact on symptoms, morbidity and mortality.¹⁸ Among COPD comorbidities, cardiovascular diseases (eg, chronic heart failure [CHF] and coronary heart disease) and mood disorders (eg, depression and anxiety) could contribute to exercise limitation and then impact 6MWT performance.^{18,19} Recent results from the ECLIPSE study demonstrated that FEV₁, modified Medical Research Council (mMRC) dyspnea score, COPD severity, depression and emphysema score on quantitative CT were associated with a 6MWD <350 m.¹⁰ Individual comorbidities were not specifically assessed, but patient-reported cardiovascular diseases were surprisingly not associated with a low 6MWD.

The purpose of the present study was to analyse the contribution of demographic data, symptoms, lung function, nutritional status and specifically comorbidities including cardiovascular diseases to the 6MWD and EID in a real-life cohort of COPD patients, using only usual parameters obtained in routine practice. A better knowledge of the correlates of 6MWT main variables could help to predict a low performance during the 6MWT and provide a better understanding of the determinants involved in exercise tolerance in COPD.

Methods

The Initiatives BPCO cohort

COPD subjects were recruited from the Initiatives BPCO cohort, a prospective real-life French cohort of clinically and spirometry-diagnosed COPD patients from 20 centers: 17 university hospitals, 2 general hospitals and 1 rehabilitation center. The details of this cohort have been previously described.^{20,21} In short, COPD subjects were

recruited at stable condition with no history of exacerbation in the previous 4 weeks, and with a diagnosis of COPD based on a post-bronchodilator FEV₁/FVC ratio <0.7.²² Exclusion criteria were a main diagnosis of bronchiectasis, asthma or other chronic respiratory diseases.

A standardized case report form was used to record demographic data, risk factors including tobacco history, respiratory symptoms, history of acute exacerbations of COPD during the previous year, health-related quality of life, anxiety and depression, spirometry and plethysmographic lung volumes according to American Thoracic Society/European Respiratory Society (ATS/ERS) standards,²³ 6MWT and comorbidities including sleep apnea syndrome, congestive HF, coronary artery disease, hypertension and diabetes mellitus. Physician investigators identified comorbidities from clinical assessment and patient files. Dyspnea was assessed by the mMRC scale²⁴ ranging from 0 to 4. Health-related quality of life was evaluated by the Saint George's Respiratory Questionnaire (SGRQ) ranging from 0 to 100. Anxiety and depression were assessed by the Hospital Anxiety Depression (HAD) questionnaire.^{25,26} The ADO score (age, dyspnea and obstruction) was calculated according to the original description.²⁷ The 6MWT was performed by experienced respiratory nurses according to ATS guidelines except for duplication, and the following variables were collected: end of 6MWT dyspnea assessed by a modified Borg scale from 0 to 10, baseline SpO₂, SpO₂ minimal value and distance. This study was conducted in accordance with the Declaration of Helsinki. The procedures of this study were approved by the Ethics Committee of Versailles (France). All subjects provided informed written consent.

Selection of COPD subjects

Due to the real-life design of the Initiatives BPCO cohort, datasets do not have to be complete to include a patient. Demographic characteristics and spirometry only are mandatory at inclusion. At the time of the analysis, 1,194 COPD subjects were included in the Initiatives BPCO cohort. Because our goal was to study the impact of both lung function and comorbidities on exercise tolerance assessed by the 6MWT, we selected subjects with complete data for 6MWT, spirometry, plethysmography, comorbidities including coronary artery disease, CHF, thromboembolic history, diabetes, hypertension and

exacerbation history during the previous year. A comparison between subjects with complete data and those with incomplete data was performed.

Statistical analyses

As 6MWT parameters did not exhibit a normal distribution according to the Kolmogorov–Smirnov test, nonparametric tests were used, and distributions were described using medians and IQRs.

Univariate analyses

The comparisons of qualitative and quantitative variables between 6MWD and EID categories were compared using χ^2 or Wilcoxon tests, respectively. The variables considered in the univariate analyses were age, sex, body mass index (BMI), mMRC dyspnea scale, FEV1% pred, forced vital capacity (FVC) % pred, lung volumes (residual volume (RV), total lung capacity (TLC), RV/TLC), SpO2 at rest, exacerbation frequency, chronic bronchitis, nutritional status and physician-diagnosed comorbidities.

Multivariate analyses

Variables explaining 6MWD and EID were explored using the LOGISTIC procedure from SAS[®] 9.2 statistical software, with significant levels for entry and stay of 15% and 10%, respectively, to introduce or remove a covariate. For each score, two stepwise ordinal logistic regressions were performed starting from no and all variables. The two stepwise analyses converged to the same model. Seventeen variables were used as covariates including lung function variables as continuous variables (FEV₁ % pred, FVC % pred, RV/TLC), comorbidities as individual variables and BMI as a categorical variable (low <18.5 kg/m²; obesity >30 kg/m²). The mMRC dyspnea scale was also used. The SGRQ and HAD scores were not entered in the models due to too many missing data. A multivariate analysis with the same 17 variables was performed for 6MWD in absolute value (meters).

Results

Patients

Among 1,194 COPD subjects included from January 2005 to October 2015, 440 subjects had complete data for the variables of interest. The characteristics of these patients are reported in Table 1. Compared to patients with incomplete data, subjects with complete data had a lower age (62 [56–70] vs 65 [58–73]; $p<0.0001$) and a lower prevalence of diabetes (10.2% vs 14.9%, $p=0.02$), with no other

Table 1 Clinical and lung function data

Variable	N=440
Comorbidities (present)	
Sex male/female	72.7% (320)/ 27.3% (120)
Age	62 [56–70]
Low BMI ≤ 18.5 kg/m ²	9.1% (40)
Obesity BMI >30 kg/m ²	18.9% (83)
Smoking history (pack-years)	38.0 [23.8–55.0]
Current/ex smokers	31.2% (135)/65.8% (285)
Hypertension	36.4% (160)
Ischemic heart disease	13.4% (59)
Chronic heart failure	12.5% (55)
Diabetes	10.2% (45)
Mechanical limitation	20.9% (92)
Sleep apnea	8.4% (37)
FEV1 (L)	1.41 [0.97–1.87]
FEV1% pred	51 [36–68]
GOLD 2007 severity	
1	8.4% (37)
2	42.5% (187)
3	32.7% (144)
4	16.4% (72)
FEV1/FVC	0.51 [0.42–0.61]
FVC % pred	86 [71–102]
RV % pred	167 [131–208]
TLC % pred	114 [103–128]
RV/TLC %	55 [47–64]
mMRC (0–4)	2 [1–2]
Chronic bronchitis	66.6% (293)
Exacerbations/year	1 [0–3]
BODE score	3 [1–4]
ADO score	3 [2–5]

Note: Data reported as numbers (percentages) or median [IQRQ1–Q3].

Abbreviations: BMI, body mass index; RV, residual volume; TLC, total lung capacity; mMRC, modified Medical Research Council scale for dyspnea; BODE, body mass index, obstruction, dyspnea and exercise score; ADO, age, dyspnea and obstruction score.

difference regarding clinical and lung function variables. Among the 440 subjects included in the analyses, all GOLD spirometry grades were represented (Table 1)

with a median FEV₁ of 51% pred and an mMRC score at 2 [1; 3]. A low BMI was found in 50 subjects and obesity in 83 subjects. Previously diagnosed comorbidities were found across all GOLD grades.

6MWT

Median 6MWD was 404 m [318–480] and 146 patients (33%) walked a distance <350 m (Figure 1). End of 6MWT-related dyspnea was higher in those with a low 6MWD. Significant EID was found in 155 patients (35%). Of note, EID and low 6MWD were unrelated (Figure 2).

Univariate associations with 6MWD and EID

Several categorical and continuous variables were related to 6MWD and EID (Tables 2 and 4, Tables S1 and S2) including age, mMRC stage, SGRQ global score, exacerbation frequency, FEV₁% pred, FVC % pred and hyperinflation at rest (RV and RV/TLC).

Baseline SpO₂ was lower in patients with a low 6MWD or EID. The prevalence of cardiovascular comorbidities was similar in patients with low or preserved 6MWD, and between those with and without EID. Obesity was inversely associated with EID, whereas the prevalence of obesity was not significantly different in patients with and without a low 6MWD.

Multivariate determinants of 6MWD and desaturations

The main determinants (as indicated by significant Wald Chi-square values) were different for 6MWD and EID (Table 3A and B). The mMRC scale was predictive of a low 6MWD only. The first functional covariate was FVC for 6MWD and FEV₁ for EID. Baseline SpO₂ was significantly associated with both 6MWD and EID. Age had a positive predictive value for a low 6MWD and negative for EID. Only hypertension appeared as a positive cardiovascular predictor of EID, whereas obesity was significantly associated with less EID. Altogether, considering all independent and significant

Figure 1 Distribution of the 6MWD (m).

Abbreviations: 6MWD, 6-min walking distance; m, meters.

Figure 2 Relationship between 6MWD and EID (SpO2 min).

Abbreviations: 6MWD, 6-min walking distance; EID, exercise induced desaturation.

determinants identified by our analyses, only a low-to-moderate proportion of the 6MWD and EID results were explained with a maximal rescaled r^2 of 0.34 and 0.37, respectively. The prediction of 6MWD in absolute value (Table 4) retained age, FEV₁% pred, mMRC and baseline SpO₂, with obesity, hypertension and diabetes as additional factors of borderline significance. Adjusted r^2 of the whole model was similar at 0.33.

Discussion

In this real-life cohort of COPD patients, a low 6MWD and/or EID occurred in approximately one-third of patients (33% and 35%, respectively). Low 6MWD and the presence of EID were unrelated, and their major determinants were different but with limited predictive values. Of note, the influence of comorbidities was low.

Determinants of a low 6MWD

Our results regarding the prevalence of a 6MWD <350 m are consistent with other COPD populations, especially the ECLIPSE cohort which exhibited a 6MWD <350m in 41%

of the patients.¹⁰ The identification of determinants associated with decreased walking distance might be useful for prognosis assessment and to identify a risk of reduced physical activity,⁵ although the relationships between the amount or intensity of daytime activity and 6MWT performance remain variable among studies.²⁸ Our results from a cohort of stable COPD patients show that age, FVC, mMRC scale and baseline SpO₂ were the main determinants of a poor performance.^{29,30} Although very easy to obtain in clinical practice, these clinical and lung function correlates of 6MWD were relatively poor predictors (rescaled r^2 0.34), insufficient to reliably estimate the presence of a low 6MWD in the individual patient. FEV₁ and mMRC were significant predictors in the multivariate analyses of the Bergen cohort by Waatevik et al,³¹ but physical activity (>1–2 hrs per week) and comorbidities assessed by the Charlson index were additional predictive factors of a better 6MWD.

Contrary to what could be expected RV/TLC was unrelated to 6MWD, a finding suggesting a moderate relationship between resting and exercise-induced dynamic hyperinflation, mainly related to the level of expiratory

Table 2 Univariate comparisons for low vs high 6MWD

Variable	6MWD ≤350 m N=146	6MWD >350 m N=294	p	Desaturation N=155	No desaturation N=285	p
Sex male/female	70.5% (103)/29.5% (43)	73.8% (217)/26.2% (77)	0.469	69.0% (107)/31.0% (48)	74.7% (213)/25.3% (72)	0.199
Age	65 [58–74]	60 [54–67]	<0.0001	60 [54–67]	62 [56–71]	0.0410
BMI ≤18.5	10.3% (15)	8.5% (25)	0.543	11.6% (18)	7.7% (22)	0.175
Obesity BMI >30	23.3% (34)	16.7% (49)	0.095	13.5% (21)	21.8% (62)	0.036
Hypertension	41.8% (61)	33.7% (99)	0.096	40.0% (62)	34.4% (98)	0.242
Chronic heart failure	16.4% (24)	10.5% (31)	0.078	11.0% (17)	13.3% (38)	0.474
Ischemic heart disease	16.4% (24)	11.9% (35)	0.189	10.3% (16)	15.1% (43)	0.161
Diabetes	11.0% (16)	9.9% (29)	0.721	9.0% (14)	10.9% (31)	0.542
Exacerbations/year	2 [0–3]	1 [0–2]	0.0021	1 [0–3]	1 [0–2]	0.0235
mMRC stage	2 [1–3]	1 [1–2]	<0.0001	2 [1–3]	1 [1–2]	<0.0001
SGRQ global score	53 [42–64]	39 [27–53]	<0.0001	49 [35–59]	42 [28–56]	0.0066
	missing 19	missing 46		missing 20	missing 45	
BODE	5 [3–6]	2 [1–3]	<0.0001	4 [2–5]	2 [1–4]	<0.0001
ADO	5 [4–6]	3 [2–4]	<0.0001	4 [3–5]	3 [2–4]	<0.0001
HAD anxiety ≥10	26.7% (39)	23.8% (70)	0.414	25.2% (39)	24.6% (70)	0.864
	missing 18	missing 50		missing 22	missing 46	
HAD depression ≥10	20.5% (30)	13.6% (40)	0.169	18.1% (28)	14.7% (42)	0.649
	missing 20	missing 46		missing 22	missing 44	
FEV1 % pred	42 [31–54]	56 [41–71]	<0.0001	38 [29–52]	57 [43–71]	<0.0001
FVC % pred	74 [61–89]	90 [76–106]	<0.0001	76 [62–91]	89 [75–106]	<0.0001
RV % pred	175 [137–223]	161 [131–199]	0.0364	189 [147–238]	156 [127–187]	<0.0001
TLC % pred	113 [98–127]	115 [104–128]	0.3958	118 [106–132]	112 [100–124]	0.0012
RV/TLC %	60 [52–67]	53 [44–61]	<0.0001	61 [51–66]	53 [46–61]	<0.0001
SpO2 at rest	95 [92–96]	96 [94–97]	<0.0001	94 [92–96]	96 [95–98]	<0.0001

Notes: Data reported as percentages (numbers) or median [IQR Q1–Q3]. Significant ($P < 0.05$) shown in bold.

Abbreviations: 6MWD, 6-min walking distance; ADO, age, dyspnea and obstruction score; BMI, body mass index; BODE, obstruction, dyspnea and exercise score; HAD, Hospital anxiety and depression scale; mMRC, modified Medical Research Council scale for dyspnea; RV, residual volume; SGRQ, Saint George's Respiratory Questionnaire; SpO2, transcutaneous oxygen saturation; TLC, total lung capacity.

Table 3 (A) Multivariate analysis for low vs high 6MWD. (B) Multivariate analysis for the presence of desaturations

OR estimates			
Effect	Point estimate	95% Wald confidence limits	
A			
Age/10 years	1.953	1.510	2.527
FVC/10% pred	0.794	0.707	0.890
mMRC	1.954	1.541	2.477
SpO2 at rest	0.857	0.787	0.933
B			
Age/10 years	0.661	0.507	0.861
Obesity yes vs no	0.457	0.242	0.864
Hypertension yes vs no	1.690	1.020	2.800
FEV1/10% pred	0.674	0.590	0.770
SpO2 at rest	0.701	0.632	0.778

Abbreviations: 6MWD, 6-min walking distance; mMRC, modified Medical Research Council scale for dyspnea; SpO2, transcutaneous oxygen saturation.

flow limitation and ventilatory pattern during the test. Interestingly, hyperinflation was also unrelated to EID, probably due to the major confounding effect and contribution of FEV₁. Age represents a major confounder, as it is present in all reference equations. As a consequence, it was present in the multivariate 6MWD model.

Previous studies also focused on the impact of comorbidities. Waatevik et al demonstrated a mean 60 m reduction of 6MWD in patients with at least 2 comorbidities, using the Charlson comorbidity score.³¹ Impact of individual comorbidities was on the contrary rather modest in our model.

Unexpectedly, important comorbidities including CHF were unrelated to 6MWD. This result is in accordance with those of Spruit et al, in which pooled cardiovascular

comorbidities were unrelated to the presence of a poor 6MWD.³² Conversely, a markedly lower 6MWD was recently found in COPD patients with a reduced (<50%) left ventricular ejection fraction (397 m vs 456 m) vs those with similar GOLD severity but preserved left ventricular contractility.³³ A 30% reduction in cycle endurance time was also reported in COPD patients with coexisting CHF.³⁴ CHF is a frequent comorbidity in COPD and contributes to dyspnea, although it is often difficult to determine its specific impact in individual patients. In our study, we cannot exclude an underdiagnosis of CHF, particularly diastolic or with preserved ejection fraction, especially because of the lack of systematic echocardiography. A recent study in the CHANCE cohort from Netherlands demonstrated a significant contribution of echocardiographic right ventricular systolic pressure, timed up and go test and quadriceps endurance work in the multivariate analysis of 6MWD.³⁵ With the addition of GOLD stage, SGRQ activity, mMRC and resting lung function (FEV1, FEV1/FVC, diffusing capacity of the lung for carbon monoxide (DLCO) and PaO2), the model explained 72% of 6MWD variance. However, echocardiography and quadriceps assessment are not performed in routine practice for COPD evaluation. In addition, timed up and go test is rather considered as a surrogate than as a determinant of 6MWT. Peripheral artery disease was also associated with a lower 6MWD in the COSICONET cohort, as objectively defined by a low ankle-brachial index.³⁶

One significant limitation of the present study regarding the 6MWD data is the lack of duplicate 6MWT. This was also the case in recent large-scale studies such as ECLIPSE.¹⁰ In clinical practice, a second test is rarely performed due to time constraints. In addition, the mean gain induced by the second test is around 26 m.⁵ When

Table 4 Multivariate analysis for 6MWD in absolute value (m)

Parameter	DF	Parameter estimate	SE	t value	Pr > t
Intercept	1	100.46004	168.52394	0.60	0.5514
Age	1	-3.22696	0.46779	-6.90	<0.0001
Obesity	1	-24.05947	11.73060	-2.05	0.0409
Hypertension	1	-20.54332	9.78203	-2.10	0.0363
Diabetes	1	33.89135	15.15119	2.24	0.0258
FEV1% pred	1	1.25108	0.25561	4.89	<0.0001
mMRC	1	-31.07953	4.65525	-6.68	<0.0001
SpO2 at rest	1	5.17758	1.73057	2.99	0.0029

Note: Significant ($P < 0.05$) shown in bold.

Abbreviations: 6MWD, 6-min walking distance; mMRC, modified Medical Research Council scale for dyspnea; SpO2, transcutaneous oxygen saturation.

considering the distribution of 6MWD in our cohort, the risk of misclassification (ie, classification of a patient below the cutoff value of 350 m instead of above this cutoff value) would be limited to those who were in the 300–349 m group: as shown in Figure 2, this group contained only 61 patients. Even assuming a high (50%) rate of misclassification, this would affect <7% (30/440) of patients in our study and thus be of little influence on the multivariate analysis results. A second test is currently mainly recommended for comparison over time, according to the latest ATS/ERS technical standards.³⁷

Determinants of EID

Although the criteria used to define significant EID in the literature are heterogeneous, recent studies concur in finding a frequency of 21–39% for these events.^{13,15} The proportion of EID was in the same range in our study. Several studies demonstrated the pejorative prognostic value of EID in COPD. The most extensive analysis was performed in the Bergen COPD cohort,¹³ using EID criteria similar to ours. Their evaluation also comprised a Charlson index, arterial blood gases and bioelectrical impedance. The HR for death was 2 among patients with EID and 2.4 after adjustment for clinical data (including Charlson index), FEV1, baseline PaO2 and 6MWD. Other recent studies demonstrated a significantly worse survival in COPD subjects with EID.^{8,38,39}

A number of predictors of EID during the 6MWT have been described. Abnormal resting gas exchange is a major determinant in most studies. A baseline SpO2 value $\leq 95\%$ appeared to have a high predictive value, together with female sex, a DLCO $< 50\%$ pred, FEV1 $< 45\%$ pred and PaO2 < 10 kPa.¹⁴ A lower resting SpO2 threshold (93%) was found in the ECLIPSE cohort. Resting SpO2 was also present in our multivariate model with a significant OR (0.7).

Moderate-to-severe emphysema on quantified CT has also been found to be a significant predictor of EID,¹⁵ but at present quantitative CT is not routinely used to assess emphysema in COPD patients. Unexpectedly, obesity was negatively related to EID in our cohort. Obesity was found to be a positive predictive factor of EID in a recent multivariate analysis in the ECLIPSE cohort.¹⁵ Conversely, it was recently suggested that moderate obesity could improve dyspnea during exercise in COPD, by limiting the degree of dynamic hyperinflation during exercise.⁴⁰ Thus, the relation between obesity, exercise hyperinflation and EIDs remains to be elucidated.

Age had a moderate negative predictive value (OR 0.66 per 10 years) of EID in our patients. This finding is opposite to the reduction of 6MWD with age, which may be explained by less desaturation due to lower distance.

The only cardiovascular comorbidity significantly associated with 6MWT variables was hypertension with a 1.6 OR for EID. Hypertension could be associated with subclinical left heart diastolic dysfunction. However, no difference in 6MWT-induced desaturation was found recently in COPD patients with HF and reduced left ventricular ejection fraction.³³

In our patients, hyperinflation (RV/TLC) was not a significant determinant of 6MWT or desaturation, which was likely related to a major interaction with FEV1. Dynamic hyperinflation during exercise is currently considered as a major limiting factor, but recent data suggest a predominant role of ventilatory constraint per se (low inspiratory reserve volume), similar in patients with or without dynamic hyperinflation.⁴¹

One important strength of our study is the systematic assessment of clinical variables including comorbidities together with lung function parameters, including lung volumes. The present study has also some limitations. Most of our patients were recruited in university hospitals and therefore may not represent the global COPD population, with a lower proportion of spirometric stage I patients. The 6MWT was not performed in duplicate, which is also true for other large previous series including ECLIPSE.¹⁰ An average learning effect of 26 m has been previously observed.⁵ This small increment is unlikely to change the predictive value of our models if a second test had been performed in our cohort. A significant limitation of the present study is that the diagnosis of comorbidities was identified by physicians based on clinical evaluation and taking into account the medical history with no systematic assessment of the presence/absence and severity (for instance left ventricular ejection fraction, diastolic parameters and/or BNP measurement for CHF) of these comorbidities. However, it must be pointed out that the frequency of comorbidities in the present study is in line with other large observational studies in COPD. The Charlson index was unavailable but is obviously not used for the routine assessment of COPD patients. Furthermore, DLCO was not assessed in the present study, whereas it was found to be a significant predictor of 6MWD and desaturations in previous studies.¹⁴ It is, however, not a standard assessment tool in recent guidelines² and clinical practice.

Conclusion

In conclusion, this study shows that, although related on a statistical ground, usual clinical data and resting lung function do not adequately predict either 6MWD or desaturations during the test. The present results also confirm the complexity of 6MWT determinants in COPD and suggest a low impact of common comorbidities, particularly clinically defined HF or coronary disease. In clinical practice, 6MWT performance remains difficult to predict with routine clinical and PFT parameters.

Abbreviation list

BMI, body mass index; COPD, chronic obstructive pulmonary disease; DLCO, diffusing capacity of the lung for carbon monoxide; FRC, functional residual capacity; HAD, Hospital Anxiety Depression score; IC, inspiratory capacity; mMRC, Modified Medical Research Council dyspnea scale; RV, residual volume; SpO₂, oxygen saturation measured by pulse oximetry; TLC, total lung capacity.

Acknowledgments

The Initiatives BPCO Study Group: Brinchault-Rabin G (Rennes), Burgel P.R (Paris), Caillaud D (Clermont-Ferrand), Carré P (Carcassonne), Chanez P (Marseille), Chaouat A (Vandœuvre les Nancy), Court-Fortune I (Saint-Etienne), Cuvelier A (Rouen), Escamilla R (Toulouse), Gut-Gobert C (Brest), Jebrak G (Paris), Lemoigne F (Nice), Nesme-Meyer P (Lyon), Perez T, Le Rouzic O and Tillie-Leblond I (Professor Tillie-Leblond passed away on March 13, 2013) (Lille), Perrin C (Cannes), Pinet C (Toulon), Raherison C (Bordeaux), Roche N (Paris), Surpas P (Bayere) and Zysman M (Nancy).

This work was funded by unrestricted grants from Boehringer Ingelheim France and Pfizer France until 2015 and is now funded by Boehringer Ingelheim France.

Author contributions

All authors contributed to data analysis, drafting and revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

Disclosure

Dr Thierry Perez reports personal fees from Boehringer Ingelheim, Novartis, GSK, and Chiesi, and grants from Astra Zeneca, outside the submitted work. Professor Gaétan Deslée reports grants and personal fees from BTG/PneumRx; grants from Nuvaire; personal fees from Chiesi, grants and personal

fees from AstraZeneca, outside the submitted work. Professor Pierre Régis Burgel reports personal fees from Astra-Zeneca, Boehringer Ingelheim, Chiesi, GSK, Pfizer, Teva, Vertex, and Zambon, outside the submitted work. Professor Denis Caillaud has nothing to disclose. Dr Olivier Le Rouzic reports personal fees and non-financial support from AstraZeneca, Boehringer Ingelheim, Chiesi, Lilly, Novartis, and PulmonX; non-financial support from GlaxoSmithKlein, outside the submitted work. Dr Maeva Zysman reports personal fees and non-financial support from Boehringer Ingelheim, during the conduct of the study; grants and personal fees from Novartis, grants from Fondation pour la recherche médicale; grants from Astra Zeneca; personal fees from Chiesi, outside the submitted work. Dr Roger Escamilla has nothing to disclose. Dr Gilles Jebrak has nothing to disclose. Professor Pascal Chanez has nothing to disclose. Dr Isabelle Court-Fortune reports grants and personal fees from Boehringer Ingelheim, during the conduct of the study. Dr Graziella Brinchault-Rabin has nothing to disclose. Dr Pascale Nesme-Meyer reports personal fees from Boehringer Ingelheim, outside the submitted work. Mr Jean Louis Paillasseur reports grants from iBPCO association, during the conduct of the study. Professor Nicolas Roche reports grants from Boehringer Ingelheim (France), during the conduct of the study. The authors report no other conflicts of interest in this work.

References

1. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and global analysis. *Eur Respir J*. 2006;28(3):523–532. doi:10.1183/09031936.06.00124605
2. GOLD. Global strategy for the diagnosis, management and prevention of COPD, global initiative for chronic obstructive lung disease (GOLD);2019 [Update 2019]. Available from: <http://goldcopd.org>. Accessed February 5, 2019
3. GOLD. Global strategy for the diagnosis, management and prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2010; 2010. Available from: <http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html>. Accessed March 22, 2011.
4. Fotheringham I, Meakin G, Punekar YS, Riley JH, Cockle SM, Singh SJ. Comparison of laboratory- and field-based exercise tests for COPD: a systematic review. *Int J Chron Obstruct Pulmon Dis*. 2015;10:625–643. doi:10.2147/COPD.S70518
5. Singh SJ, Puhan MA, Andrianopoulos V, et al. An official systematic review of the European Respiratory Society/American Thoracic Society: measurement properties of field walking tests in chronic respiratory disease. *Eur Respir J*. 2014;44(6):1447–1478. doi:10.1183/09031936.00150414
6. Cote CG, Casanova C, Marin JM, et al. Validation and comparison of reference equations for the 6-min walk distance test. *Eur Respir J*. 2008;31(3):571–578. doi:10.1183/09031936.00104507
7. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. *N Engl J Med*. 2004;350(10):1005–1012. doi:10.1056/NEJMoa021322

8. Andrianopoulos V, Wouters EF, Pinto-Plata VM, et al. Prognostic value of variables derived from the six-minute walk test in patients with COPD: results from the ECLIPSE study. *Respir Med*. 2015;109(9):1138–1146. doi:10.1016/j.rmed.2015.06.013
9. Crisafulli E, Iattoni A, Venturelli E, et al. Predicting walking-induced oxygen desaturations in COPD patients: a statistical model. *Respir Care*. 2013;58(9):1495–1503. doi:10.4187/respcare.02321
10. Spruit MA, Watkins ML, Edwards LD, et al. Determinants of poor 6-min walking distance in patients with COPD: the ECLIPSE cohort. *Respir Med*. 2010;104(6):849–857. doi:10.1016/j.rmed.2009.12.007
11. Celli B, Tetzlaff K, Criner G, et al. The 6 min-walk distance test as a chronic obstructive pulmonary disease stratification tool. Insights from the COPD biomarker qualification Consortium. *Am J Respir Crit Care Med*. 2016;194(12):1483–1493. doi:10.1164/rccm.201508-1653OC
12. Casanova C, Aguirre-Jaime A, de Torres JP, et al. Longitudinal assessment in COPD patients: multidimensional variability and outcomes. *Eur Respir J*. 2014;43(3):745–753. doi:10.1183/09031936.00096913
13. Waatevik M, Johannessen A, Gomez Real F, et al. Oxygen desaturation in 6-min walk test is a risk factor for adverse outcomes in COPD. *Eur Respir J*. 2016;48(1):82–91. doi:10.1183/13993003.00975-2015
14. Andrianopoulos V, Franssen FM, Peeters JP, et al. Exercise-induced oxygen desaturation in COPD patients without resting hypoxemia. *Respir Physiol Neurobiol*. 2014;190:40–46. doi:10.1016/j.resp.2013.10.002
15. Andrianopoulos V, Celli BR, Franssen FM, et al. Determinants of exercise-induced oxygen desaturation including pulmonary emphysema in COPD: results from the ECLIPSE study. *Respir Med*. 2016;119:87–95. doi:10.1016/j.rmed.2016.08.023
16. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. *Ann Intern Med*. 1980;93(3):391–398.
17. Takigawa N, Tada A, Soda R, et al. Distance and oxygen desaturation in 6-min walk test predict prognosis in COPD patients. *Respir Med*. 2007;101(3):561–567. doi:10.1016/j.rmed.2006.06.017
18. Fabbri LM, Luppi F, Beghe B, Rabe KF. Complex chronic comorbidities of COPD. *Eur Respir J*. 2008;31:204–212. doi:10.1183/09031936.00114307
19. Maurer J, Rebbapragada V, Borson S, et al. Anxiety and depression in COPD current understanding, unanswered questions, and research needs. *Chest*. 2008;134(4):43S–56S. doi:10.1378/chest.08-0342
20. Burgel PR, Nesme-Meyer P, Chanez P, et al. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. *Chest*. 2009;135(4):975–982. doi:10.1378/chest.08-2062
21. Perez T, Burgel PR, Paillassier JL, et al. Modified medical research council scale vs Baseline Dyspnea index to evaluate dyspnea in chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis*. 2015;10:1663–1672. doi:10.2147/COPD.S82408
22. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. *Am J Respir Crit Care Med*. 2007;176:532–555. doi:10.1164/rccm.200703-456SO
23. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. *Eur Respir J*. 2005;26(2):319–338. doi:10.1183/09031936.05.00034805
24. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical research council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. *Thorax*. 1999;54(7):581–586.
25. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's respiratory questionnaire. *Am Rev Respir Dis*. 1992;145(6):1321–1327. doi:10.1164/ajrccm/145.6.1321
26. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand*. 1983;67(6):361–370.
27. Puhon MA, Garcia-Aymerich J, Frey M, et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. *Lancet*. 2009;374(9691):704–711. doi:10.1016/S0140-6736(09)61301-5
28. Watz H, Pitta F, Rochester CL, et al. An official European respiratory society statement on physical activity in COPD. *Eur Respir J*. 2014;44(6):1521–1537. doi:10.1183/09031936.00046814
29. Mahler DA, Ward J, Waterman LA, Baird JCD. Longitudinal changes in patient-reported Dyspnea in patients with COPD. *COPD*. 2012;9:522–527. doi:10.3109/15412555.2012.701678
30. Jones P, Miravittles M, van der Molen T, Kulich K. Beyond FEV(1) in COPD: a review of patient-reported outcomes and their measurement. *Int J Chron Obstruct Pulmon Dis*. 2012;7:697–709. doi:10.2147/COPD.S32675
31. Waatevik M, Johannessen A, Hardie JA, et al. Different COPD disease characteristics are related to different outcomes in the 6 min walk test. *COPD*. 2012;9(3):227–234. doi:10.3109/15412555.2011.650240
32. Spruit MA, Polkey MI, Celli B, et al. Predicting outcomes from 6 min walk distance in chronic obstructive pulmonary disease. *J Am Med Dir Assoc*. 2012;13(3):291–297. doi:10.1016/j.jamda.2011.06.009
33. Mesquita R, Franssen FM, Houben-Wilke S, et al. What is the impact of impaired left ventricular ejection fraction in COPD after adjusting for confounders? *Int J Cardiol*. 2016;225:365–370. doi:10.1016/j.ijcard.2016.10.016
34. Oliveira MF, Arbex FF, Alencar MC, et al. Heart failure impairs muscle blood flow and endurance exercise tolerance in COPD. *COPD*. 2016;13(4):407–415. doi:10.3109/15412555.2015.1117435
35. McNamara RJ, Houben-Wilke S, Franssen FME, et al. Determinants of functional, peak and endurance exercise capacity in people with chronic obstructive pulmonary disease. *Respir Med*. 2018;138:81–87. doi:10.1016/j.rmed.2018.03.032
36. Houben-Wilke S, Jorres RA, Bals R, et al. Peripheral artery disease and its clinical relevance in patients with chronic obstructive pulmonary disease in the COPD and systemic consequences-comorbidities network study. *Am J Respir Crit Care Med*. 2017;195(2):189–197. doi:10.1164/rccm.201602-0354OC
37. Holland AE, Spruit MA, Troosters T, et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. *Eur Respir J*. 2014;44(6):1428–1446. doi:10.1183/09031936.00150314
38. Golpe R, Perez-de-Llano LA, Mendez-Marote L, Veres-Racomonde A. Prognostic value of walk distance, work, oxygen saturation, and dyspnea during 6 min walk test in COPD patients. *Respir Care*. 2013;58(8):1329–1334. doi:10.4187/respcare.02290
39. Casanova C, Cote C, Marin JM, et al. Distance and oxygen desaturation during the 6-min walk test as predictors of long-term mortality in patients with COPD. *Chest*. 2008;134(4):746–752. doi:10.1378/chest.08-0520
40. Ora J, Laveneziana P, Wadell K, Preston M, Webb KA, O'Donnell DE. Effect of obesity on respiratory mechanics during rest and exercise in COPD. *J Appl Physiol*. 2011;111(1):10–19. doi:10.1152/jappphysiol.01131.2010
41. Guenette JA, Webb KA, O'Donnell DE. Does dynamic hyperinflation contribute to dyspnoea during exercise in patients with COPD? *Eur Respir J*. 2012;40(2):322–329. doi:10.1183/09031936.00157711

Supplementary materials

Table S1 Univariate logistic analysis for low 6MWD

Effect	OR estimates	95% Wald confidence limits		Wald Chi-square	Pr > ChiSq
Female vs male	1.177	0.757	1.828	0.5227	0.4697
Age	1.056	1.034	1.079	24.4536	<0.0001
Low BMI yes vs no	1.232	0.628	2.416	0.3690	0.5435
Obesity yes vs no	1.518	0.929	2.481	2.7719	0.0959
Hypertension yes vs No	1.414	0.940	2.126	2.7609	0.0966
Ischemic heart disease yes vs No	1.456	0.830	2.554	1.7137	0.1905
Heart failure yes vs No	1.669	0.940	2.965	3.0538	0.0805
Diabetes yes vs No	1.125	0.590	2.145	0.1273	0.7213
OSAS yes vs No	0.840	0.403	1.751	0.2167	0.6416
Chronic bronchitis yes vs No	1.192	0.779	1.825	0.6567	0.4177
FEV1% pred	0.966	0.955	0.977	35.1247	<0.0001
FEV1/FVC	0.073	0.015	0.360	10.3363	0.0013
FVC % pred	0.971	0.961	0.981	33.2866	<0.0001
RV (L)	1.214	1.047	1.409	6.5540	0.0105
TLC % pred	1.004	0.990	1.019	0.3466	0.5560
mMRC	2.234	1.798	2.776	52.6517	<0.0001
Exacerbations/patient/year	1.148	1.038	1.270	7.2482	0.0071

Note: Significant P-values shown in bold.

Abbreviations: BMI, body mass index; OSAS, obstructive sleep apnea syndrome; FEV1 % pred, forced expiratory volume in one second, percentage of predicted; FVC % pred, forced vital capacity, percentage of predicted; RV (L), residual volume in liters; TLC (L), total lung capacity in liters; TLC % pred, total lung capacity, percentage of predicted; mMRC, modified Medical Research Council dyspnea scale; 6MWD, 6-min walking distance.

Table S2 Univariate logistic analysis for the presence of significant desaturations

Effect	OR estimates	95% Wald confidence limits		Wald Chi-square	Pr > ChiSq
Sex female vs male	1.327	0.861	2.046	1.6424	0.2000
Age/10 years	0.840	0.690	1.024	2.9788	0.0844
Low BMI yes vs no	1.571	0.815	3.028	1.8185	0.1775
Obesity yes vs no	0.564	0.329	0.967	4.3370	0.0373
Hypertension yes vs no	1.272	0.850	1.905	1.3651	0.2427
Ischemic heart disease yes vs no	0.648	0.352	1.193	1.9404	0.1636
Heart failure yes vs no	0.801	0.436	1.472	0.5121	0.4742
Diabetes yes vs no	0.814	0.419	1.580	0.3712	0.5424
OSAS yes vs no	0.480	0.214	1.078	3.1579	0.0756
Chronic bronchitis yes vs no	1.084	0.714	1.643	0.1425	0.7058
FEV1% pred	0.952	0.940	0.964	58.3708	<0.0001
FEV1/FVC	0.003	<0.001	0.018	41.5437	<0.0001
FVC % pred	0.973	0.964	0.983	29.4992	<0.0001
RV (L)	1.346	1.158	1.563	15.0655	0.0001
TLC (L)	1.001	0.999	1.004	1.1197	0.2900
RV/TLC %	1.008	0.997	1.019	1.8886	0.1694
mMRC	1.490	1.231	1.804	16.7205	<0.0001
Exacerbations/patient/year	1.110	1.005	1.226	4.2674	0.0388

Note: Significant P-values shown in bold.

Abbreviations: BMI, body mass index; OSAS, obstructive sleep apnea syndrome; FEV1 % pred, forced expiratory volume in one second, percentage of predicted; FVC % pred, forced vital capacity, percentage of predicted; RV (L), residual volume in liters; TLC (L), total lung capacity in liters; mMRC, modified Medical Research Council dyspnea scale.

International Journal of Chronic Obstructive Pulmonary Disease**Dovepress****Publish your work in this journal**

The International Journal of COPD is an international, peer-reviewed journal of therapeutics and pharmacology focusing on concise rapid reporting of clinical studies and reviews in COPD. Special focus is given to the pathophysiological processes underlying the disease, intervention programs, patient focused education, and self management

protocols. This journal is indexed on PubMed Central, MedLine and CAS. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journal>